Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
76 hedge funds and large institutions have $631M invested in Adaptimmune Therapeutics in 2018 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 26 increasing their positions, 19 reducing their positions, and 12 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
81% more capital invested
Capital invested by funds: $348M → $631M (+$283M)
42% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 12
37% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 19
7% more funds holding
Funds holding: 71 → 76 (+5)
0.73% more ownership
Funds ownership: 9.26% → 9.99% (+0.73%)
27% less call options, than puts
Call options by funds: $721K | Put options by funds: $983K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$14.6M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$11.4M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$7.93M |
| 4 |
Millennium Management
New York
|
+$5.88M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$5.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$9.17M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.03M |
| 3 |
AG
Artal Group
Luxembourg
|
-$4.68M |
| 4 |
GAMA
Graticule Asia Macro Advisors
New York
|
-$2.03M |
| 5 |
Axa
Paris,
France
|
-$1.98M |
ADAP Hedge Fund Activity: Q1 2018 in Review
76 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q1 2018, worth a combined $631M — up 81% from $348M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ADAP positions and 12 closed out — a net gain of 5 holders — while 26 added to existing stakes and 19 trimmed.
The largest buyer was Matrix Capital Management Company, adding an estimated $14.6M. The largest seller was OrbiMed, cutting an estimated $9.17M.
- 76 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q1 2018, up from 71 in Q4 2017.
- Funds reported $631M of Adaptimmune Therapeutics stock for Q1 2018, up 81% quarter-over-quarter.
- 17 funds opened new Adaptimmune Therapeutics positions in Q1 2018 and 12 closed out, a net change of +5 holders.
- The largest Adaptimmune Therapeutics buyer in Q1 2018 was Matrix Capital Management Company, an estimated $14.6M added.
- The largest Adaptimmune Therapeutics seller in Q1 2018 was OrbiMed, an estimated $9.17M sold.
Based on aggregated 13F filings for Q1 2018.